exam 3 lecture 7 Flashcards
biologics
meds derived from living organisms
recombinant proteins, peptides, blood factors, vaccines, oliognulceotides, cell-based therapy
biotech drugs or biopharmaceuticals
importance of biologics
top 200 drug sales 2018 –> 73 were biologics
top 100 drug sales in 2003 –> 5 were biologics
monoclonal antibodies (mAb)
two light chains (L)
two heavy chains (H)
linked by SS bonds
antigen binding occurs through variable domain(V) at (CDR)
antibody drug conjugates
trojan horse
linker on ADC attaches to cytotoxic agent
combine target specificity of mAb with efficacy of small molecule drugs
can use mAb fragments rather than whole mAb
cytokines
IL, INF
neulasta, epogen, avonex, rebif, humatrope
insulins
a-chain and b-chain linked by ss bonds
alpha helical structure –> readily associates to form dimers, hexamers
insulin analogs
lispro insulin: fast acting insulin analog, lys and pro on c-terminus are reversed
aspar insulin: fast acting insulin analog, pro on c-terminus of b-chain mutated to asp
glargin insulin: long acting, asn on a21 mutated to gly
peptides
short proteins less than 50 AAs
some secondary structure, no higher order structure
some chemical modifications
peptide vs peptide analog
peptidomimetic (telaprevir)
peptide like structure
vaccines
types: inactivated, attenuated, toxoid, conjugate, subunit
differ widely in size and structure
can be much larger than other biologics
cell therapies –> new biologics
car-t cell therapies
- remove immune cells from patient’s blood,
- genetically program to fight cancer cells,
- multiplied + infused into patient,
- newly programmed car-t cells kill cancer cells
oligonucleotides –> new biologics
used to treat spinal musclar atrophy
dosage forms for biologics
dosing is usually parenteral: except oral vaccines
peptides and proteins cannot be given orally
common dosage forms:
- solution for injection, pen/autoinjector, pre-filled syringe, lyphilized powder
solution formulation
simple and least expensive
convienent for patients and hospital bc they don’t need reconstitution
can be inspected prior to administration
clinical concerns for solutions
efficacy, sterility, side effects (dose-limiting immune response)
pain from injection
formulation concerns solutions
all clinical concerns
stability: aggregation, chem stability, shelf-life, storage conditions
manufacturing: cost, manufacturing time
formulation variables solutions
solution properties: ph, ionic strength, drug conc., volume, excipients.
container: materials
Storage conditions: refrigerator vs room, frozen
formulation variables: pH
rate of sCT degradation depends on pH
pH of maximum stability is 3-4 –> not a pH for injection
additive makes stability worse
formulation variables: concentration
beta lactoglobulin is a milk protein
higher concentration of it results in increased and greater aggregation
SC delivery required small volumes –> mAb concentrations risk aggregation
formulation variables: excipients
stabilize proteins
promote interactions with water and stabilize native protein structure
excipients that bind to proteins can lead to denaturation
exception: protein binding to ligands can stabilize native structure
Eythropoetin
erythropoetin (EPO, Epoetin) is used to treat anemia in renal disease
anti-EPO antibodies
reduces drug effect and that of any naturally occur EPO
Pure red cell aplasia (PRCA)
results in sudden onset anemia, death
increasesd PRCA has been associated with change in container closure (stopper)
what if solution formulation does not work
store at fridge temperature
freeze
freeze-dry or spray-dry to create dried powder for reconstitution
re-engineer protein molecule
abandon drug candidate